Prime Minister Narendra Modi said on Thursday that the combination of biotechnology and biomass is an important part of the foundation of Visit Bharat's dreams.

New Delhi, Jan 9 (PTI) Prime Minister Narendra Modi on Thursday released the genome sequencing data of 10,000 Indian nationals and said it will be a milestone in the field of biotechnology research.

A view of a data center in Qingyang, Gansu province. LANG BINGBING/XINHUA China's latest efforts to construct a national data infrastructure are expected to fully unleash the value of massive data ...

The Neonatal Data Analysis Unit forms part of the Neonatal Medicine Research Group led by Professor Neena Modi at the Chelsea and Westminster campus of Imperial College London. The Neonatal Data ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

The leading data integration platform for ETL / ELT data pipelines from APIs, databases & files to data warehouses, data lakes & data lakehouses. Both self-hosted and Cloud-hosted.

If this is the first time you have submitted data in the collection, you will need to contact us to obtain valid login details. In an email, provide your name, telephone number and training ...

Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Add a description, image, and links to the field-data-collection topic page so that developers can more easily learn about it.

Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

According to GlobalData, Phase II drugs for Unspecified B-Cell Lymphomas does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data ...